SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-21-009030
Filing Date
2021-02-12
Accepted
2021-02-12 16:39:14
Documents
2
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea135532-sc13dfsdev_gemini.htm SC 13D 123879
2 JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS ea135532ex11_gemini.htm EX-11 11608
  Complete submission text file 0001213900-21-009030.txt   137292
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Subject) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91633 | Film No.: 21628537
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111 415 877 4887
FS Development Holdings, LLC (Filed by) CIK: 0001820810 (see all company filings)

IRS No.: 851613057
Type: SC 13D